Lawsuit Filed Over Hemophilia Drug
The complaint, originally filed under seal in Delaware Chancery Court on Aug. 4, accused Baxter of backing out of a joint agreement in order to promote its own hemophilia drug Advate.
“As a result of Baxter’s breaches of contract, GI has suffered substantial damage,” Genetics Institute said.
Starting in 1989, Genetics Institute agreed to supply Baxter with Factor VIII, the protein necessary to form blood clots. Baxter then...
To view the full article, register now.